Skip to main content

Advertisement

Table 2 Biodistribution and tumor to non-target organ ratios for 64Cu/NOTA-monomer and 64Cu/NOTA-dimer 2

From: Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging

Organ 64Cu/NOTA-monomer 64Cu/NOTA-dimer 2
  30 min 30 min 120 min
  Unblocked Blocked a Unblocked Unblocked Blocked a
Blood 1.35 ± 0.47 12.72 ± 3.42 3.13 ± 0.67 1.34 ± 0.15 3.32 ± 2.78
Plasma 2.48 ± 0.63 21.69 ± 6.16 5.27 ± 1.27 2.45 ± 0.27 6.14 ± 4.89
Adrenal 4.29 ± 1.13 16.57 ± 0.37 9.23 ± 5.01 11.56 ± 4.91 3.63 ± 2.43
Fat 0.65 ± 0.54 3.22 ± 4.29 1.86 ± 0.81 0.68 ± 0.61 3.46 ± 2.74
Kidney 10.42 ± 1.29 75.13 ± 36.20 17.02 ± 6.24 26.37 ± 8.13 23.00 ± 5.37
Spleen 1.63 ± 1.82 3.29 ± 0.16 5.31 ± 1.43 5.50 ± 2.61 3.31 ± 0.95
Pancreas 5.10 ± 2.50 4.57 ± 2.65 4.60 ± 0.57 13.35 ± 7.38 1.43 ± 0.61b
Liver 5.38 ± 8.12 8.12 ± 0.70 41.79 ± 5.58 23.11 ± 2.36 12.20 ± 2.78b
Heart 1.05 ± 0.91 4.65 ± 0.33 4.42 ± 1.59 2.68 ± 0.13 1.58 ± 0.80
Lungs 1.77 ± 1.28 14.26 ± 1.58 7.22 ± 2.73 5.07 ± 1.58 34.42 ± 23.31
Muscle 0.40 ± 0.33 3.45 ± 2.06 1.59 ± 1.16 1.13 ± 0.62 1.41 ± 0.98
Bone 0.43 ± 0.46 1.52 ± 0.58 0.78 ± 0.21 0.83 ± 0.19 1.15 ± 0.44
Brain 0.08 ± 0.07 0.63 ± 0.09 0.38 ± 0.06 0.22 ± 0.05 0.16 ± 0.09
Tumor 1.79 ± 0.46 4.82 ± 0.91 3.95 ± 0.26 6.28 ± 2.87 3.25 ± 1.15
Tumor/blood 1.49 ± 0.41 0.38 ± 0.01b 1.39 ± 0.30 4.09 ± 1.79 1.04 ± 0.60b
Tumor/muscle 7.42 ± 3.17 1.59 ± 0.44b 3.95 ± 1.98 4.46 ± 1.86 2.31 ± 1.46
Tumor/liver 2.07 ± 1.13 0.60 ± 0.13 0.10 ± 0.01 0.22 ± 0.07 0.24 ± 0.09
Tumor/kidney 0.17 ± 0.04 0.07 ± 0.01b 0.28 ± 0.09 0.22 ± 0.11 0.12 ± 0.03
Tumor/pancreas 0.44 ± 0.17 1.18 ± 0.32b 0.89 ± 0.11 0.36 ± 0.09 1.80 ± 0.39b
  1. Biodistribution and ratios are at 30 and 120 min post-injection. aBlocked by injecting 0.1 μmol of non-radiolabeled peptide together with the radiopeptide. bCo-injection significantly lowered the uptake of the same organ for the corresponding tracer (p < 0.05).